ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 1549

Improvement in Joint Activity in Adults with Systemic Lupus Erythematosus Treated with Anifrolumab: Results from a Real-World Cohort
Abstract Number: 1550

Real-World Outcomes of Anifrolumab in Systemic Lupus Erythematosus Patients at Toronto Lupus Program
Abstract Number: 1551

Disease Burden and Treatment Preferences for Systemic Lupus Erythematosus: Results from a Global Real-World Survey
Abstract Number: 1552

Treatment With Anifrolumab Prevents Long-Term Cardiovascular Damage Accrual Compared With Real-World Standard of Care in Patients With Systemic Lupus Erythematosus: Findings From the LASER Study
Abstract Number: 1553

Circulating Monocyte Level Is Associated With Pulmonary Vascular Disease and Right Ventricular Dysfunction in Systemic Sclerosis
Abstract Number: 1554

Demographic, Clinical, and Mortality Trends in Scleroderma Patients with Gastric Antral Vascular Ectasia (GAVE): A National Inpatient Analysis
Abstract Number: 1555

Prevalence of Organ Involvement and Baseline Predictors of Disease Progression in Patients with Limited Cutaneous Systemic Sclerosis: Insights from the CONQUER Database
Abstract Number: 1556

Latent Profiles of Parenchymal Abnormalities and Vascular Features Measured by Quantitative CT Identifies a Subgroup of Systemic Sclerosis Patients With a Greater Lung Function Decline Over Time
Abstract Number: 1557

Association between Thoracic Muscle and Fat Area and Density and Pulmonary Function in Systemic Sclerosis
Abstract Number: 1558

Gastrointestinal Symptom Severity Is Associated With Worse Patient-Reported Outcomes And Dietary Patterns In Systemic Sclerosis: A Single Center Prospective Study
Abstract Number: 1559

Anti-Cytolethal Distending Toxin Antibodies in Systemic Sclerosis: Associations with Gastrointestinal Disease and Immune Dysregulation
Abstract Number: 1560

Longitudinal assessment of circulating fibroblast activation protein in systemic sclerosis-associated interstitial lung disease
Abstract Number: 1561

Usefulness of HRCT in screening of interstitial lung disease in patients with systemic sclerosis without risk factors of clinical suspicion
Abstract Number: 1562

Vasodilation with Prostanoids Influences Progression of Systemic Sclerosis-Associated Interstitial Lung Disease: a EUSTAR Cohort Study
Abstract Number: 1563

RESET-SSc: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), A Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Systemic Sclerosis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].